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 As under-utilised providers, community pharmacists are not primarily rewarded for 
delivering health care.
 Community pharmacists are increasingly responsible for effective, safe, and efficient use 
of medicines.
 Progress in transforming the roles of community pharmacists in chronic disease 
management remains limited.
 Countries are gradually introducing limited payment reforms encouraging patient-
centred services.
 Moving forward, challenges include integrating pharmacists into primary care; 
developing tiered pharmacist services; and adopting new remuneration mechanisms. 
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Chronic conditions are the largest cause of death and disability in the world.(1) Across 
countries with advanced economies, an estimated one of five people have multiple chronic 
conditions—a situation that is expected to worsen as populations age. Management of chronic 
conditions is among the most pressing challenges of healthcare systems worldwide. There is a 
need for interventions, strategies, and policies that more effectively manage and treat the rising 
numbers of people with multiple chronic conditions, but considerable inertia remains in 
policymakers’ stewardship of the chronic disease crisis. 
One reform that holds particular potential is the involvement of community pharmacists 
(pharmacists who work outside of a hospital setting). Concerns about the sustainability of 
healthcare expenditures have fuelled interest in expanding the patient-centered responsibilities 
of community pharmacists. Community pharmacists constitute a significant portion of the 
health care workforce. In the United States (US), there are approximately 110,000 practicing 
community pharmacists(2) as compared to roughly 250,000 primary care physicians.(3) Given 
the increasing demands on the time of primary care physicians and nurses, policymakers in a 
number of countries have started to tap into the potential of other professionals who can 
contribute to appropriate and cost-effective use of medicines. 
Pharmacists are well suited to assume an expanded role in the healthcare system. Indeed, 
despite their current role as “retailers”, taking on patient-centered responsibilities is 
commensurate with the profession’s extensive training and expertise. Although educational 
requirements vary by country, the total length of formal training is typically five to six years, 
with an additional two or three years required to specialize or obtain an advanced degree.(4) In 
addition, licensure is often required through a national or regional examination before the right 










to practice is granted. Unlike hospital pharmacists who are increasingly integrated into clinical 
care teams, and rewarded for caring for patients, community pharmacists have traditionally 
worked in isolation from the rest of the primary care workforce – predominantly responsible 
for retailing and dispensing medicines. Pharmacists are the only health professionals who are 
not primarily rewarded for delivering health care.
Recognizing this untapped potential,(5, 6) a number of countries have recently implemented 
policies to expand the roles of community pharmacists in order to facilitate coordinated care 
delivery. While these reforms vary in their focus and scope, they are similar in their aim to 
benefit from pharmacists as primary health care professionals. A system-wide policy agenda is 
needed to align the roles, objectives, and incentives of health professionals and devise an 
expanded role for community pharmacists. Such approaches are emerging, albeit slowly. In this 
paper, we investigate recent reform efforts in Australia, Canada, England, the Netherlands, 
Scotland, and the US. These countries have recently undertaken a range of reforms with the 
objective of equipping community pharmacists with expanded roles and responsibilities when 
caring for people with multiple chronic conditions. 
Our paper has three sections. The first section describes the analytic framework and methods 
used to collect country-level information on the current and future roles and responsibilities of 
community pharmacists. The second section sets out the results of the cross-country 
comparison and outlines the policy developments surrounding the key components for 
expanding the patient-centered responsibilities of community pharmacists. The final discussion 
section highlights opportunities and challenges ahead for the role of the community pharmacy 
profession in integrated primary care, and outlines the roadmap for overcoming important 
practical challenges when moving towards equipping community pharmacists with expanded 
roles. 












The analytical framework proposed by Mossialos and colleagues (7) guided our country 
selection and data collection. This framework builds upon and broadly parallels the domains of 
Pharmaceutical Care and Total Pharmaceutical Care models.(8, 9) Pharmaceutical care is often 
described as “the responsible provision of drug therapy for the purpose of achieving definite 
outcomes that improve a patient’s quality of life.”(8) Total pharmaceutical care is “the delivery 
of a comprehensive range of services that result in the maximum possible contribution to the 
health of a nation’s population within the limits of the health care delivery structure.”(9)
We explored two complementary objectives of an expanded role for community pharmacists: 
(1) ensuring the effective, safe, and efficient use of medicines, and (2) the prevention and
management of chronic disease (Box 1). 
Country selection
Based on this framework, we conducted a tightly focused review of the academic and grey 
literature. The objective of this first stage exploratory review was to identify the latest policy 
developments on community pharmacists across Europe and North America and inform the 
selection of country cases. We first searched international websites including but not limited to 
the World Health Organization, International Pharmaceutical Federation, and European 
Pharmacists Forum to identify international developments and country-level professional 
associations. We then reviewed the publications of professional pharmacist organizations such 
as the Royal Pharmaceutical Society in the UK to identify the most prominent policy examples.  










Coupled with a review of academic publications as well as policy documents from 
governmental agencies, six countries were selected for further investigation: Australia, Canada, 
England, The Netherlands, Scotland, and the US. These countries have in common that they 
have started to equip community pharmacists with additional patient-centered roles essential 
for caring for people with multiple chronic conditions. 
The aim of this country selection was not to provide a comprehensive list of policy 
developments surrounding the community pharmacy profession. Scandinavian countries, for 
example, have adopted policies equipping pharmacists with patient-centered responsibilities. 
(11, 12) Rather than providing an exhaustive description of policy initiatives in developed 
countries, this paper offers an in depth analysis within a set of countries that are at various 
levels of policy development. The objective is to understand the emergence of policy changes 
related to developing an expanded role for pharmacists in order to contribute to the safe, 
effective, and efficient use of drugs.
The experiences of the six countries selected in this article carry important lessons for 
policymakers in other settings who are devising interventions and strategies for incorporating 
community pharmacists into the care of people with multiple chronic conditions. 
2.2.Country questionnaires and data collection
We carried out primary data collection in the six selected countries. The information provided 
in this paper is based on the information received from national experts, contributing to this 
cross-country report as co-authors. National experts were selected based on their (1) prominent 
publications advocating for a new vision for the community pharmacist profession in their 
country; (2) knowledge of or visible participation in the latest policy developments equipping 
community pharmacists with new patient-centered roles; and (3) active academic research on 










the evaluation of past or ongoing policy initiatives around the expanded roles of community 
pharmacists. One national expert for each country provided detailed responses to a 
questionnaire on the country-level roles and responsibilities of community pharmacists. 
Experts were asked about key elements of the economic and political national context within 
which community pharmacists operate, legislative and policy developments (passed or 
underway) regarding the two dimensions of the framework in their settings, any evaluated 
impacts of community pharmacy interventions, and context-specific facilitators or barriers to 
change for further policy and practice developments. Data collection took place between July 
2013 and April 2014. The roles of community pharmacists are evolving in the six countries 
selected and this article presents a picture of the situation as of early 2015.
3. RESULTS
We reviewed recent national policy developments with regards to the two dimensions of the 
framework in Australia, Canada, England, The Netherlands, Scotland, and the US. Community 
pharmacists in the six countries examined have made significant progress in achieving an 
expanded role in ensuring the effective, safe, and efficient use of medicines. However, 
developments in establishing a role within the prevention and management of chronic disease
have been slow and piecemeal. 
3.1.Effective, Safe, and Efficient Use of Medicines
Dispensing and retailing remain the core functions of the pharmacy profession, and the 
selected countries have made great strides in equipping community pharmacists with tasks 
aimed at ensuring the effective, safe, and efficient use of medicines (Table 1). 










The Canadian Medical, Pharmacists and Nurses Associations issued a joint statement in 2003 to 
define the scope of shared practices for health professionals including community pharmacists, 
triggering legislative and regulatory changes. Since then, Canadian community pharmacists have 
adopted joint care responsibilities with physicians, especially in the area of prescribing.(10) As 
health care is under provincial jurisdiction, each province has developed its own model for 
pharmacist medication management, prescribing, and reimbursement.(11) Canadian 
pharmacists are also increasingly able to renew, adjust or substitute physicians’ prescriptions, 
although again the scope of pharmacist practice varies according to province.(12) For example, 
since 2007, community pharmacists in Alberta have implemented an expanded prescribing 
model focusing on adapting existing prescriptions and emergency prescribing. Accredited 
community pharmacists in Alberta can also independently initiate and manage drug therapy.(13)
When independently prescribing medications, pharmacists are required to carefully document 
their interaction with the patient, including the rationale, assessment, drug information, and 
follow-up plan with other providers. Three Canadian provinces have recently authorized 
community pharmacists to order and interpret laboratory tests, with similar legislation under 
way in three other provinces.(11)
The UK government has had a long-standing interest in developing and exploiting community 
pharmacy. The impetus for expanding the role of community pharmacists came with the 
publication of specific pharmacy policies for the National Health Service in England in 2000 
(“Pharmacy in the Future”) and Scotland in 2002 (“The Right Medicine”). Since 2005, 
community pharmacists in England have been providing professional services in three tiers: 
essential, advanced, and enhanced.(14) Every pharmacy must offer the essential services, 
including primary and repeat dispensing, support for self-care, and healthy lifestyle promotion. 
Offering enhanced and advanced services is optional, and requires pharmacists to obtain 










additional certification. Medication use review is the only advanced service, whereas several 
interventions such as treatment of minor ailments, chronic disease screening, smoking cessation 
services, and supplementary prescribing are considered enhanced services (Box 2). 
Qualified pharmacists in England and Scotland have been able to independently prescribe 
medications since 2006.(15) In 2012, reforms in both countries allowed pharmacists to also 
prescribe certain controlled drugs. The UK’s pharmacy regulator, the General Pharmaceutical 
Council, accredits prescribing training courses and identifies individuals with supplementary or 
individual prescribing rights on the register of pharmacists. 
Community pharmacy practice in Australia includes provision of drug information and clinical 
interventions.(16, 17) Community pharmacists also have the authority to perform emergency 
prescribing and continued dispensing and to provide additional services, including medication 
use reviews. While Australian community pharmacists are encouraged to carry out prescribing 
for minor ailments, no formal scheme of financial and professional support is in place for such 
tasks. Collaborative medication reviews are also widespread between community pharmacies 
and primary care practices.(16) Research evaluating the impact of collaborative medication 
reviews indicates that such services improve prescribing, and have the potential to reduce 
health service use and medication costs for patients with multiple chronic conditions.(18, 19)
The Australian data also show that a majority of general practitioners have accepted and 
implemented the medication changes proposed by community pharmacists as part of these 
collaborative agreements.(20)
Community pharmacists in the Netherlands have faced a number of roadblocks in recent years. 
In 2008, a “preference policy” (tender-based purchase of medicines) was adopted by the health 
insurers to reduce national prescription drug spending by limiting the number of reimbursed 
medicines per beneficiary. Despite its well-intentioned objectives, this policy had unintended 










consequences and considerably limited the number and scope of patient-centered services 
offered by community pharmacists as these services had to be financed out of the pharmacy’s 
retailing-related income. Responding to this challenge, the Royal Dutch Pharmacists 
Association spearheaded reform efforts and devised a new vision for the community pharmacy 
profession in an influential white paper in 2011. In this report, the Association proposed a new 
vision for the profession and promoted the role of community pharmacists beyond the 
distribution of medicines. Currently, community pharmacists in the Netherlands are allowed to 
renew prescriptions for certain products such as insulin and contraceptives.(21) Despite limited 
progress on the prescribing front, recent legislation is aimed at giving pharmacists access to 
laboratory test results and indications for prescribing, both of which are essential to monitor 
the safety of medication use. Although these changes have been approved in parliament, and 
there are increasing numbers of pharmacists and general practitioners that cooperate closely, 
pharmacist access to data is not yet widely implemented, mostly due to a lack of adequate 
training and necessary information technologies. A recent study on drug-related hospital 
admissions has illustrated that medication reviews are now increasingly performed by  Dutch 
community pharmacists.(22)
In the US, there are recent developments on both federal and state levels. At the federal level, 
the Medicare Prescription Drug Benefit (Medicare Part D), which came into effect in 2006, 
introduced Medication Therapy Management (MTM) as a quality improvement strategy at the 
federal level.(23) Similar to medication use review programs commonplace in other countries, 
MTM in the US aims to prevent adverse effects associated with prescription drug therapy and 
improve adherence for Medicare beneficiaries. During comprehensive medication review, 
pharmacists can identify safety, effectiveness, and cost issues about prescription drug therapy 
for beneficiaries enrolled in prescription drug plans. Existing evidence from systematic reviews 










suggests that such practices reduce medication-related problems, improve adherence, and 
achieve better clinical outcomes.(24) In the Asheville Project, patients with diabetes had 
improved outcomes following the initiation of community-based pharmaceutical care 
services.(25) Expanding the number of community pharmacists who participate in MTM and 
the number of eligible Part D enrollees who obtain a comprehensive medication review is a 
focus of policy initiatives.  
At the state level, an increasing number of Collaborative Drug Therapy Management 
agreements between pharmacists and providers, which vary greatly by state, now allow 
pharmacists to perform clinical tasks such as initiating, modifying, or continuing drug therapy 
and ordering laboratory tests.(26, 27) Many states also allow community pharmacists to provide 
emergency prescriptions to patients, although varying levels of restrictions apply in different 
states.  
3.2.Chronic Disease Prevention and Management
There is a strong case for equipping community pharmacists with clinical tasks aimed at 
managing chronic diseases. Previous research showed that patients with diabetes visit 
community pharmacists five times more frequently than other primary healthcare 
professionals.(28) Yet, with the exception of England and Scotland, progress in transforming 
the roles of community pharmacists in chronic disease management has been limited. 
In the Netherlands, despite widespread enthusiasm among professional organizations in 
equipping community pharmacists with key responsibilities in managing chronic conditions,
recent efforts did not go beyond implementing a number of national campaigns for the 
detection of diabetes and asthma (such as free testing in pharmacies). Recently pharmacists are 
becoming members of so called ‘care groups’ in which primary care physicians, pharmacists, 
and other health care providers engage in defining and coordinating the care for chronic 










diseases (especially chronic obstructive pulmonary disease, diabetes and cardiovascular risk 
management). Progress has been slow in Canada as well. A small pilot study in the province of 
Nova Scotia showed that a variety of health care professionals agree that community 
pharmacists have a role to play in the management of patients with diabetes, including 
counselling; providing feedback to physicians; monitoring and reinforcing the messages of 
other professionals; giving patients information; and educating them about their diabetes.(29)
Barriers to further progress range from practical considerations (lack of time, funding, and 
workforce) to limited patient awareness and inadequate training of pharmacists.(29)
In Australia, community pharmacies offer smoking cessation and weight management 
programs as part of their routine practice. Two pilot studies assessing the potential for the 
involvement of community pharmacists in chronic disease control programs demonstrated the 
important role that community pharmacists can play in managing some conditions, as long as 
there is a strong coordination system in place between the healthcare professionals 
involved.(30)
Notably, community pharmacists in the six countries we examine are increasingly assuming care 
coordination responsibilities. Such tasks are critical for managing the complex medication 
regimens of individuals with multiple chronic conditions (and, perhaps, multiple physicians) 
and those transitioning between care settings or levels of care. Professional organizations and 
governmental agencies have recently recognized the collaboration between health 
professionals—including community pharmacists—as a priority in Australia and Canada 
(Table 2; Box 3). In the Netherlands, specific guidelines outlining the provision of coordinated 
care in community pharmacies recommend the transfer of medication-related information 
between pharmacists and other primary and secondary care providers.(31)










In the US, limited progress is occurring towards engaging community pharmacists in tasks 
aimed at chronic disease prevention. So far, employers have been the driving force behind a 
number of developments. For example, some community pharmacists now conduct health 
screenings for body mass index as well as laboratory tests for cholesterol levels, blood pressure, 
and glucose levels; such tests are often reimbursed by employers as part of wellness programs. 
However, policy developments surrounding community pharmacists’ involvement in chronic 
disease prevention and management remain fragmented. 
Recent reforms in Scotland and England have gone further than those in other countries. In 
2013, Scotland’s National Health Service introduced the Chronic Medication Service, which 
formalized the role of community pharmacists in the management of individual patients with 
chronic conditions.(32) This service involves patients with long-term conditions registering 
with the community pharmacies of their choice; generation of an individual pharmaceutical care 
plan; and collaborative management of medicines with patients’ primary care providers. The 
National Health Service in England introduced a New Medicine Service in 2011 for patients 
receiving a medicine for the first time for a chronic condition.(33) Within this scheme, 
community pharmacists support patients over several weeks to ensure safe and effective use of 
drugs. The New Medicine Service is targeted to medicines for the treatment of chronic 
respiratory and cardiovascular illnesses. 
3.3.Paying Pharmacists for Patient-Centered Services
Historically, remuneration in community pharmacy settings has been primarily based on 
retailing and dispensing functions in all countries considered. Although limited, recent reform 
efforts in some of our country cases have gradually introduced new payment mechanisms to 
encourage the adoption of patient-centered services in community pharmacist settings. 










The level of reimbursement for patient-centered services offered in community pharmacists in 
Canada varies greatly across provinces, in part because the 10 provincial regulatory bodies have 
different legislative and professional standards.(13, 34) In England, the introduction of the 
three-tier pharmacy contract changed the existing remuneration mechanisms for community 
pharmacists. Prior to 2005, legislation limited payments for patient-centered services to the 
reimbursement of dispensed medicines and fees for dispensing-related activities, creating a 
product-centric pharmacy practice. After 2005, medication use reviews were introduced on a 
set fee-for-service basis.
The Australian government introduced new compensation mechanisms for community 
pharmacists conducting medication reviews in 1997 in residential care and in 2001 for all 
community patients.(16) Since 2011, the Pharmacy Pr ctice Incentive Program has been 
providing incentives on a fee-for-service basis for the delivery of patient-centered services in 
five core areas: diabetes, respiratory disease, cardiovascular disease, mental health conditions 
and health promotion. It is expected that the range of areas will increase in the coming years. 
The “Working with others” mechanism was also introduced in 2011 as an annual payment for 
community pharmacists who collaborate with other health professionals.
The remuneration system in place in The Netherlands is not designed to encourage pharmacists 
to provide patient care as it is mostly aimed at reimbursing dispensing services. Although 
community pharmacists can get marginal additional reimbursement for a limited number of 
patient-centered services such as medication reviews, the level of reimbursement differs by 
health insurer and generally pharmacists are allowed to offer these services to a limited number 
of patients. In addition, primary care providers are easy to access in The Netherlands and are 
exempt from co-payments, which further hinders the development of community pharmacists’ 










role in safe, effective, and efficient use of medications, and in the prevention and management 
of chronic conditions. 
Currently, in the US, pharmacist remuneration is primarily based on retailing functions, which 
are determined by payers, pharmacy benefit managers, or health plans. In community settings, 
pharmacists may provide patient counseling and self-care recommendations, but 
reimbursement is not available.  Many community pharmacies now provide vaccinations and 
this is reimbursed by health insurers.  Increasingly, contracted private MTM companies link 
community pharmacists with health plans and provide reimbursement for MTM services. 
Depending on the MTM provider and the Part D plan, community pharmacists may be 
reimbursed for comprehensive medication review, phone follow-up on new prescriptions or 
resolving drug-related problems. Some programs have linked community pharmacies to 
hospitals/healthcare systems by focusing on medication reconciliation during care transitions, 
but these practices are not standardized. 
3.4.Interprofessional Education
Although developments remain limited, Canada has been at the forefront of interprofessional 
education. Many Canadian universities offer training in interdisciplinary care to nursing, 
medical, and pharmacy students.(10) Similar developments are occurring in the US, where there 
is a greater emphasis on training health professionals in interdisciplinary collaborative 
teams.(35) There are already several universities in the US offering training courses in 
interprofessional education.(36) Postgraduate training courses in the US include community 
pharmacy residencies focused on advancing skills in collaborative patient care. In the 
Netherlands interdisciplinary education is limited to one week during the curriculum, and is 
sometimes only optional.











This cross-country comparison of policy developments highlights the increasing appetite for 
reconfiguring the responsibilities of the pharmacist profession, better integrating pharmacists 
into the healthcare system, and equipping community pharmacists with patient-centered roles 
commensurate with their training and expertise in medications.  
Figure 1 summarizes where the six countries selected in this cross-country comparison stand 
with respect to three aspects which are crucial for the expansion of the role of community 
pharmacists: (1) a dedicated remuneration system; (2) primary care integration; (3) 
multidisciplinary education. The six countries considered in this article are at different stages of 
policy implementation. Notably, England and Scotland have been at the forefront of defining 
different “tiers” of community pharmacist roles in terms of both (1) effective, safe, and 
efficient use of medicines and (2) prevention and management of chronic conditions. 
Policymakers in England and Scotland have also aligned these new responsibilities with specific 
remuneration systems. Canada and the US have pioneered multidisciplinary pharmacy 
education—an essential component to ensure that future health care professionals view 
community pharmacists as members of integrated care teams. Australia has made progress on a 
number of different fronts, and specifically in the area of integrating community pharmacists 
within the primary care system. Despite slow progress on the implementation front, a number 
of policy developments are currently underway in The Netherlands and policymakers are 
actively engaged in developing legislation to expand the roles of community pharmacists.
Paradoxically, with the exception of the US and the Netherlands, community pharmacists are 
often not playing a key role in the recent policy evolution of accountable care. Although quality 
improvement efforts are prominent on the political agenda in the US, progress thus far remains 
limited. For example, there are several ongoing initiatives which aim to improve the quality of 










prescription drug therapy by holding health plans accountable for the care they provide to 
patients. The National Quality Forum recently developed pharmacy-specific quality indicators, 
primarily used by health plans, aimed at monitoring the safety of prescription drug therapy, 
promoting generic drug use, and improving adherence. The Pharmacy Quality Alliance is 
actively pursuing the development and adoption of metrics of community pharmacy services 
for use in quality improvement, benchmarking, and pay-for-performance benchmarks.(37)
In the Netherlands, Dutch Healthcare Inspectorate and the Royal Dutch Pharmacists 
Association developed indicators to evaluate the quality of care in community pharmacies.(38)
Introduced nationally in 2008, the indicators were designed to provide pharmacist-reported 
data on the structure, process and outcome of care at the level of a community pharmacy.(38)
When moving forward, policy-makers should consider a number of important practical 
objectives: effectively integrating community pharmacists into primary care; developing a 
shared vision for different levels of pharmacist services; and devising new remuneration 
mechanisms and performance-based incentive mechanisms.(39) Table 3 provides a roadmap 
for the expansion of the role of pharmacists, detailing the mechanisms and processes by which 
these three objectives were achieved in the countries, and the facilitators or barriers to 
successful policy implementation.
4.1.Interprofessional Collaboration
There is a need to foster collaboration between different provider groups by integrating 
community pharmacists into the wider primary care workforce. Without such collaboration, 
equipping community pharmacists with new responsibilities risks fragmenting primary care 
services. 










One aspect of collaboration is data sharing facilitated by information technology. Enabling 
patients' health information to be electronically transferred to and from community pharmacies 
is crucial. In the Netherlands, the transfer of information between health professionals is 
becoming a reality. In particular, community pharmacists and primary care physicians 
increasingly consult to ensure appropriate medication use, including periodic pharmacotherapy 
consultation. 
Another key component of collaboration is interdisciplinary education of nursing, medical, and 
pharmacy students. Such training that fosters collaborative work is increasingly commonplace 
in Canada. In addition to initiatives at provincial level – especially in Ontario and Alberta – a 
national interprofessional competency framework was established in 2014, which serve as key 
facilitators for successful development and implementation of interprofessional collaboration 
curricula around the country. 
4.2.Differentiation of Pharmacist Services
Although all six countries have gradually expanded the responsibilities of community 
pharmacists in patient care, there is still no consensus on how best to differentiate services at 
different pharmacy practice tiers.(40) Reflecting the government’s long-standing interest in 
strengthening the community pharmacy profession, in 2005, England established the pharmacy 
contract to recognize different levels of pharmacy services, accompanied by respective sets of 
tasks and required skills. In addition to this contract, awareness, availability, and attitude of 
local community pharmacists were key facilitators of successful implementation. (47)
Such clearly defined responsibilities would help community pharmacists and other health 
professionals in other countries understand their roles, establish performance indicators, and 
design adequate educational programs.(40) Professional and regulatory organizations have so 
far been instrumental in defining the core competencies of community pharmacists. Learning 










from other professional groups such as those involved in national health technology 
assessments, forming international collaborations, and forging consensus among national and 
local community pharmacist organizations could lead to the identification of a tiered set of 
professional standards to form the basis of future policy discussions.
4.3.Revised Payment Model
One of the primary obstacles to more widespread implementation of patient-centered roles for 
community pharmacists is the current remuneration model.(41) Pharmacy has previously been 
recognized as the only health profession that is primarily reimbursed for the sale of a product 
rather than provision of a service..(16) Thus, an adequate remuneration model is needed to 
balance the income from dispensing and retailing medicines with that from an expanded service 
to patients. 
Pharmacist remuneration in most settings is primarily based on dispensing. In 2010, the 
Canadian Academy of Health Sciences (CAHS) underlined the necessity of building a 
remuneration system for non-medical health professionals in an attempt to integrate them into 
the primary care system by aligning funding and provider remuneration with patient outcomes.
One promising financing model would involve the funding of community pharmacists to be 
part of the primary care system.(42) A subsequent from CAHS developed a conceptual 
framework for innovative models of care to optimize scope the scope of practice, including 
flexible legislative frameworks and alternative funding models.(43) In the US, the latest health 
care reforms (Affordable Care Act) aims to shift reimbursement of health care providers from 
fee-for-service payment toward rewards for improved quality, outcomes, and efficiency.(44)
Introducing policy changes to formally expand the role of community pharmacists cannot be 
achieved at once, especially in this economic context. Rather, countries should consider 
adopting a tiered implementation strategy to facilitate the transformation of the community 










pharmacy practice. The first tier could represent the high priorities of moving beyond the 
traditional retailing and dispensing of medications. It could include monitoring the safety, 
accuracy and quality of drug dispensing and use. The second tier could consist of overseeing 
the appropriate indication and adherence to medicinal prescriptions – an essential component 
of chronic disease prevention and management. Finally, more focused prevention and 
management of chronic disease could constitute the third tier. Implementation will have to be 
carefully designed, taking into account national circumstances, data availability, and the 
legitimate concerns of community pharmacists regarding their professional supply and the 
required structural changes. An important consideration is to accompany policy changes with 
carefully designed and executed evaluation strategies. 
CONCLUSIONS
Community pharmacists are underutilized professionals: they have the skills and position in the 
healthcare system to engage further in the provision of care for people with multiple chronic 
diseases. The magnitude and range of reform efforts across the countries covered in this article 
demonstrate the enthusiasm and political will to equip community pharmacists with patient-
centered roles. Integration of community pharmacists into primary care faces the following 
obstacles: lack of established collaboration among providers; inadequate compensation models 
that fail to reward the delivery of patient-centered services in the pharmacy setting; and lack of 
a shared vision for different levels of pharmacist services. Our policy review highlights the need 
to devise targeted efforts to formally integrate community pharmacists into the primary 
healthcare system and make community pharmacy a “health hub destination for the 
future.”(45)  
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Figure 1. Advances in Involving Community Pharmacists in Prevention and 
Management of Chronic Diseases
AUS: Australia; CAN: Canada; EN: England; NL: Netherlands; SCOT: Scotland; US: United 
States.




























Box 1. Analytic Framework
Expanded Roles and Responsibilities for Community Pharmacists
1. Ensuring the effective, safe, and efficient use of medicines:
a. monitoring medication use (including avoiding medication errors, minimizing 
adverse reactions, avoiding drug interactions, monitoring dosage, providing 
emergency prescription refill, renewing or extending medication, advising 
patients with over-the-counter medications); 
b. ensuring appropriate indication (including recommending additional or 
alternative drug or non-drug strategy, promoting generic use); 
c. improving adherence (including reinforcing prescribing instructions, 
educating/counseling patients about the importance of continuity of 
treatment, improving literacy about drugs, including comprehensible 
communication of risks, providing information on cost, effectiveness or 
safety, inquiring about satisfaction about therapy); and 
d. promoting safety, accuracy and quality of medications (including managing 
drug distribution systems, ensuring careful purchasing of medications to 
prevent counterfeit use, adopting quality management systems for timely and 
effective procurement and storage). 
2. Prevention and management of chronic disease: 
a. symptom management and continuity of care (including advising patients with 
minor ailments, referring patients to other health professionals, presenting 
drug regimens to a care team or physician, developing a care and follow-up 
plan); and 
b. chronic disease management and self-care (e.g., managing asthma care, 
managing mental illness, monitoring blood pressure, ordering and interpreting 
tests for chronic conditions such as cardiovascular diseases and diabetes, and 
administering drugs). 










Box 2. Medication Use Review in England: Early Experience, Research, and Revision
Early Experience
In 2005, the National Health Service of England introduced the Medicine Use Review and 
Prescription Intervention Service (MUR) with the objective of improving patient knowledge 
and use of prescription drugs. In a pharmacist-selected, opportunistic face-to-face consultation 
with patients, MUR focuses on establishing the patient’s use, understanding, and experience of 
taking drugs; identifying, discussing, and resolving any issues; identifying side effects and drug 
interactions; and improving the clinical and cost-effectiveness of drugs. Within this scheme, 
certified pharmacists with a private consultation facility receive a set fee per MUR consultation 
completed within an annual maximum per facility. 
Research and Evaluation
Despite initial enthusiasm, the uptake of the MUR—both in terms of the number of 
participating community pharmacies and the number of consultations undertaken—was initially 
low, with independent pharmacists lagging behind groups.1 Initial evaluations suggested that 
lack of support from and collaboration with primary care physicians and workload constraints 
were among important barriers to wider adoption of MUR.1,2 Recent research also showed that 
consultations were brief encounters, dominated by closed-ended questions.3 Although some 
patients felt more assured about drug therapy as a result of MURs, such consultations did not 
have a notable impact on patients’ knowledge of their prescribed medicines.3











In October 2011, new legislation targeted certain groups of patients to receive MUR, including 
those receiving high-risk medicines such as non-steroidal anti-inflammatory or anticoagulant 
drugs and those discharged from hospital in the previous eight weeks who had had changes 
made in their prescribed medication. 
References: 
1Latif A, Boardman H. Community pharmacists' attitudes towards medicines use reviews and 
factors affecting the numbers performed. Pharm World Sci. 2008;30(5):536-43.
2Bradley F, Wagner AC, Elvey R, Noyce PR, Ashcroft DM. Determinants of the uptake of 
medicines use reviews (MURs) by community pharmacies in England: a multi-method study. 
Health Policy. 2008;88(2-3):258-68.
3Latif A, Pollock K, Boardman HF. The contribution of the Medicines Use Review (MUR) 
consultation to counseling practice in community pharmacies. Patient Educ Couns. 
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Box 3. Integrating Pharmacists into Primary Care in Australia: Evidence from Pilot 
Projects
Community pharmacists in Australia are gradually recognizing the importance of patient-
centered tasks such as medication reviews and disease management programs,1 a move largely 
driven by influential pharmacist professional associations.2,3 In a concerted effort to influence 
policymaking, professional associations and governmental agencies are jointly commissioning 
research projects to investigate the potential of community pharmacists in providing care for 
patients with asthma, diabetes, cardiovascular diseases, and mental illnesses. In a notable 
example, the TEAMCare pilot demonstrated that pharmacists and other primary care 
professionals can work together to improve older patients’ outcomes.4 Another Australian pilot 
proposed a role for community pharmacists within a general practice to provide multiple risk 
management advice and improve patient safety.5 The evidence from these pilots fed into the 
Professional Collaboration section of the Fifth Community Pharmacy Agreement in 2012 and 
will influence policy in the coming years. The Agreement proposes the creation of a National 
Primary Health Care Professional Forum to unify the different primary care providers and 
develop a strategic shared vision on the delivery of primary care in Australia at national, 
regional, and local levels.6
References: 
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in Australia: A health hub destination of the future. Research in Social and Administrative 
Pharmacy. 2013; 9(6):863-75.
2The Pharmacy Guild of Australia. The Roadmap: the strategic direction for community 
pharmacy. Canberra: The Pharmacy Guild of Australia, 2010.
3Pharmaceutical Society of Australia. Issues paper on the future of pharmacy in Australia. 
Canberra: Pharmaceutical Society of Australia, 2010.
4McDonald P, Rigby D, Roush P, Watts I. GP referral ina group of older community-dwelling 
people. Australian Pharmacist. 2000;19:107-11.
5Ackerman E, Williams ID, Freeman C. Pharmacists in general practice - a proposed role in the 
multidisciplinary team. Aust Fam Physician. 2010;39:163-4.
6Francis C, Cannings J, Jessop R, Thew S, Li J, Benrimoj C. Professional Collaboration. 
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Table 1. Summary of the Expanded Scope of Community Pharmacy Practice in Promoting Effective, Safe, and Appropriate Use of Medicines  
Note: Data provided as of 2013.  
Source: Adapted from Canadian Pharmacists Association. Pharmacists' Medication Management Services. Environmental Scan of Activities across Canada. Ottawa: Canadian Pharmacists Association; 2013. 
 Australia Canada England Netherlands Scotland US 
Provide emergency 
prescription refills 
Yes Implemented in 9 of 13 provinces and 
territories. Pending legislation in 
Manitoba. 
Yes Yes  Yes Yes 
Renew/extend 
prescriptions 
Renewal of prescriptions is not 
allowed however extension can 
be considered part of continued 
supply (CS). CS has been 
introduced in July 2013. 
Pending legislation in all 
Australian territories.  
Authorized in all provinces, except in 
Nunavut and Yukon. 
Yes Yes, but renewal is 




Yes Yes, in 47 states and 
the District of 





No Authorized, except in Northwest 
Territories, Nunavut, and Yukon. Pending 
legislation in Manitoba, Quebec, and 
Prince Edward Island 
Yes Yes, but within 
boundaries and 
close contact with 
prescribers. 
Yes Yes, in all states 
Make therapeutic 
substitution 
No Authorized in 6 of 13 provinces and 
territories. Pending legislation in Quebec. 
Yes No Yes Yes, in all states 
Minor ailments prescribing Yes, but there is no formal 
scheme or payment system in 
place to support this.    
Authorized in 3 of 13 provinces and 
territories (Alberta, Saskatchewan and 
Nova Scotia). Pending legislation in 
Quebec. 
Yes No Yes Yes, in all states 
Initiate prescription drug 
therapy 
No  Authorized in 4 provinces. Pending 
legislation in Manitoba and Quebec.  
Yes No Yes Yes, in 33 states and 
the District of 
Columbia 
Order and interpret lab 
tests 
Yes Ordering and interpreting tests is 
authorized in Alberta, New Brunswick, 
and Nova Scotia. Pending legislation in 
Manitoba, Ontario, and Quebec. 
Yes Yes, but not 
reimbursed 
Yes Yes, in 31 states 
Administer a drug by 
injection 
No Authorized in 5 provinces. Pending 
legislation in Manitoba, Quebec, Prince 
Edward Island, and Newfoundland and 
Labrador. 
No No No No 
Table 1









Table 2. Coordinating Primary Care Delivery in Canada: Evidence from Pilot Projects 
Pilot project Objectives Main findings 
IMPACT (Integrating 
Family Medicine and 
Pharmacy to Advance 
Primary Care 
Therapeutics) 
To determine the feasibility of 
integrating community 
pharmacists into primary care 
practice teams 
Interprofessional collaborations 
which include community 
pharmacists improve the level of 
care, medication safety, and cost-





To assess whether the 
intervention of a trained 
pharmacist as a consultant to a 
primary care physician could 
reduce the number of daily 
medication units taken by 
elderly patients, as well as costs 
and healthcare use 
Integrating pharmacists into in-
office primary care practice (by 
serving as consultants to primary 
care physicians) was feasible to 




Asthma Treatment in 
Hinton and Edson) 
To determine the effect of a 
multidisciplinary asthma 
management programme 
initiated by community 
pharmacists on asthma control 
No differences in asthma control 
were found but the multidisciplinary 
and community-based component 
of the programme was successful in 
fostering collaboration among 
primary care professionals.3 
References: 
1Dolovich L, Pottie K, Kaczorowski J, Farrell B, Austin z, Rodriguesz C, et al. Integrating 
family medicine and pharmacy to advance primary care therapeutics. Clinical Pharmacology & 
Therapeutics. 2008;83(6):913-7. 
2Sellors J, Kaczorowski J, Sellors C, Dolovich L, Woodward C, Willan A, et al. A randomized 
controlled trial of a pharmacist consultation program for family physicians and their elderly 
patients. Canadian Medical Association Journal. 2003;169(1):17-22. 
3Charrois T, Newman S, Senthilselvan A, Tsuyuki RT. Improving asthma control in the rural 
setting: the BREATHE (Better Respiratory Education and Asthma Treatment in Hinton and 


















Process by which policy objective was achieved in successful countries Facilitators to successful policy 
implementation 
















Many Canadian universities offer training in interdisciplinary care to nursing, 
medical, and pharmacy students. Collaborative work was also fostered by a number 
of federal/provincial-level reports. For example, the Federal/provincial advisory 
committee developed a framework for collaborative health human resource 
planning in 2005. In addition to initiatives at provincial level – especially in Ontario 
and Alberta – a national interprofessional competency framework was established 
in 2014.  
 
In the Netherlands, enabling patients' health information to be electronically 
transferred to and from community pharmacies is a national priority, allowing 
community pharmacists and primary care physicians to increasingly consult each 
other. In addition, a national electronic patient record is being developed, which 
will contain information on prescription drugs and relevant clinical information.  
 
In Australia, the National Health Policy encourages the integration of community 
pharmacists through for instance payment for referral by the primary care 
physicians for Home Medicines Reviews; or review and reporting by pharmacist to 
primary care physicians; or payment for “collaboration with others” as part of the 
Pharmacy Practice Incentives. 
In Canada, facilitators include flexible 
regulatory frameworks, emerging alternative 
financing and reimbursement approaches as 
well as the publication of the national 
interprofessional competency framework in 
2014. 
 
In the Netherlands, community pharmacists 
and primary care physicians have been 
cooperating through Pharmacotherapy Quality 
Circles. They are also increasingly located in the 
same Community Health Care Centres.  
 
In Australia, facilitators include remuneration 
for pharmacist services, employment of practice 
facilitators and computer-dedicated programs. 
In Canada the limited 
development of electronic 
medical records could be a 
barrier to the integration of 
community pharmacists.  
 
In the Netherlands, choice and 
competition across service 
providers pose a barrier to 
effective integration of 
pharmacists into primary care 
and are responsible for 

















England recognizes different levels of pharmacy services, accompanied by 
respective sets of tasks and required skills: essential, advanced, and enhanced. 
 
The government has had a long-standing interest in developing and exploiting 
community pharmacy. As early as 1992, it established a Joint Working Party with 
the Royal Pharmaceutical Society on pharmaceutical care.(46) 
 
The greatest impetus for expanding the role of community pharmacists came with 
the publication of specific pharmacy policies for the NHS in England and Scotland 
in the early 2000s. The period between 1995 and 2005, which preceded the 
introduction of England’s 3-tier NHS Pharmacy Contractual Framework, 
witnessed a range of local community pharmacy initiatives, involving evidence 
generation, pilots and service development. 
The pharmacy contract served as the primary 
driver to successful implementation and 
adoption.(47)  
 
Relationships between commissioners (those 
who decide which services should be provided, 
who should provide them, and how they should 
be paid for) and local pharmaceutical 
committees were important facilitators.  
 
Awareness, availability, and attitude of local 
community pharmacists were facilitators of 
successful implementation. 
Access to funding and adequate 
resources to commission new 
community pharmacist services 
were identified as key 
barriers.(47)  
 
Support from primary care 
physicians was also identified as 













metrics that can 
be tied to payment 
models 
The Netherlands introduced a set of 42 indicators to measure the quality of care 
provided by community pharmacists in 2008. The indicators were developed in 
collaboration between the Dutch  
Healthcare Inspectorate and the Royal Dutch Pharmacists Association.  
 
 
In the United States, the National Quality Forum developed pharmacy-specific 
quality indicators, primarily used by health plans. Similarly, the Pharmacy Quality 
Quality improvement is a shared objective in 
the health care system. The Ministry of Health 
introduced quality indicators for all sectors of 
healthcare, without singling out community 
pharmacy.  
 
The Affordable Care Act aims to reward 
improved quality, outcomes, and efficiency. 
Lack of clarity around how the 
quality indicators will be used, 




Lack of knowledge of changing 
reimbursement models, as they 
Table 3








ptprovision rather than 
dispensing 
Alliance is actively pursuing the development and adoption of metrics of 
community pharmacy services for use in quality improvement and pay-for-
performance benchmarks. 
  
NQF was created (1999) by a group of public and private health leaders, arising 
from work accomplished during President Clinton’s initiative for a Consumer Bill 
of Rights. Pharmacy Quality Alliance was created (2006) by the stakeholders of 
Medicare Part D to help ensure its quality. 
 
The Center for Medicaid and Medicare seeks to 
achieve improved quality, improved health and 
lower costs, as known as the triple aim.  
  
Healthcare reimbursement continues to move 
away from fee-for-service with no link to 
quality, toward global outcomes-based 
population incentives, using key performance 
targets and quality indicators as the basis for 
aspects of reimbursement. 
 
In pharmacy, EQuIPP is a platform developed 
to improve performance in community 
pharmacies via comparisons of quality 
indicators across groups of pharmacies and/or 
plans.  
 
Large pharmacy chain organizations are likely to 
have the vision, information technology and 
human resources to adapt to quality-based 
reimbursement models. 
may not directly impact front-
line pharmacists yet.  
 
Information systems are 
necessary within practices to 




performance and compensation 
may not align with newer 
reimbursement models. 
 
 
 
